KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: A Phase 3 Randomized Clinical Trial.

Nick Panay, Hadine Joffe, Pauline M Maki, Rossella E Nappi, JoAnn V Pinkerton, James A Simon, Claudio N Soares, Rebecca C Thurston, Maja Francuski, Cecilia Caetano, Kelly Genga, Claudia Haberland, Nazanin Haseli Mashhadi, Kaisa Laapas, Susanne Parke, Christian Seitz, Judith Schwarz, Lineke Zuurman

JAMA Intern Med 185(11) 1319-1327

PMID40920404
PMCIDPMC12418220
DOI10.1001/jamainternmed.2025.4421
发表日期2025-09-08
入排依据:未发现恶性肿瘤人群证据。
已检查 2 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 flow diagram;Figure 2:生活质量量表图。
摘要

摘要

IMPORTANCE: There is an unmet need for long-term, safe, effective, and hormone-free treatments for menopausal symptoms, including vasomotor symptoms (VMS) and sleep disturbances. OBJECTIVE: To evaluate the 52-week efficacy and safety of elinzanetant, a dual neurokinin-targeted therapy, for treating moderate to severe VMS associated with menopause. DESIGN, SETTING, AND PARTICIPANTS: OASIS-3 was a double-blind, placebo-controlled, randomized phase 3 clinical trial that was conducted at 83 sites in North America and Europe from August 27, 2021, to February 12, 2024, and included postmenopausal women aged 40 to 65 years who were seeking treatment for moderate to severe VMS (no requirement for a minimum number of VMS events per week). The data were analyzed on March 11, 2024. INTERVENTION: Once-daily oral elinzanetant, 120 mg, or matching placebo for 52 weeks. MAIN OUTCOMES AND MEASURES: The primary outcome was mean change from baseline to week 12 in the frequency of daily moderate to severe VMS, which was analyzed using a mixed model with repeated measures. Secondary end points included changes over 52 weeks in measures evaluating sleep disturbance and the effect on menopause-related quality of life. Exploratory end points included mean changes over 50 weeks in frequency and severity of daily moderate to severe VMS. Exploratory and secondary end points were analyzed using descriptive statistics. Safety was also assessed. RESULTS: Overall, 313 women (mean [SD] age, 54.6 [4.7] years; 51 [16.3%] were Black or African American, and 240 [76.7%] were White individuals; 34 [10.9%] were Hispanic or Latina) were randomized to receive elinzanetant and 315 (mean [SD] age, 54.9 [5.0] years; 44 [14.0%] Black or African American, 34 [10.8%] Hispanic or Latina, and 253 [80.3%] White individuals) to receive placebo. At week 12, the mean change from baseline in daily moderate to severe VMS frequency was -5.4 (95% CI, -6.3 to -4.5) for elinzanetant and -3.5 (95% CI, -4.1 to -2.9) for placebo; the least-squares mean difference for elinzanetant vs placebo was -1.6 (95% CI, -2.0 to -1.1; P < .001). Although no statistical hypotheses were defined, nor was the study powered to detect between-group differences for the secondary and exploratory end points, descriptive analyses showed numerical advantages for elinzanetant vs placebo for improving VMS frequency and severity over 50 weeks and sleep disturbances and menopause-related quality of life over 52 weeks. Regarding safety, elinzanetant was not associated with hepatotoxic effects, endometrial hyperplasia, or meaningful changes in bone density or bone turnover markers. Treatment-related adverse events were more common with elinzanetant than placebo (30.4% vs 14.6%); the most frequent were somnolence, fatigue, and headache. CONCLUSIONS AND RELEVANCE: The OASIS-3 randomized clinical trial expanded on findings from the 26-week OASIS-1 and OASIS-2 trials, exploring the use of elinzanetant over a longer duration and in a broader population. Elinzanetant shows promise as a treatment for moderate to severe VMS. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05030584.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1.. Trial Profile Participant screening, randomization, and participant flow. AE indicates adverse event; BMD, bone mineral density VMS, vasomotor symptoms. a One participant provided 2 reasons for exclusion from the study (screen failure and participant decision). b Did not include participants who discontinued the study drug but remained in the study and completed the posttreatment phase/follow-up. c One participant assigned to the placebo arm received elinzanetant at the week 8 visit by mistake; therefore, they were assigned to the elinzanetant, 120 mg, arm in the safety analysis set.
非 KM Figure
Figure 2Figure 2.. Mean Changes From Baseline in the Full Analysis Set Mean daily moderate to severe vasomotor symptom (VMS) frequency (A) and severity (B), Patient-Reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b (PROMIS SD-SF-8b) total T score (C), and Menopause-Specific Quality Of Life Questionnaire (MENQOL) total score (D) over 50 or 52 weeks. Weeks 49 and 50 were the last points at which the hot flash daily diary was collected. All other patient-reported outcomes were collected until end of follow-up. Mean daily VMS severity during baseline was calculated as: [(2 × number of moderate VMS) + (3 × number of severe VMS)] / (total number of moderate and/or severe VMS on that day). Mean daily VMS severity during treatment was calculated as: [(1 × number of mild VMS) + (2 × number of moderate VMS) + (3 × number of severe VMS)] / (total number of mild, moderate, and/or severe VMS on that day).
非 KM Figure